The prognostic value of C-reactive protein in renal cell carcinoma: A systematic review and meta-analysis

Hu, Qingfeng; Gou, Yuancheng; Sun, Chuanyu; Ding, Weihong; Xu, Ke; Gu, Bin; Xia, Guowei; Ding, Qiang

doi:10.1016/j.urolonc.2013.07.016

Cited by 66 publications

(42 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This implies that CRP is not an independent prognosis factor for esophageal cancer. This conclusion is correlated with other researches (Guo et al, 2013;Yu et al, 2013;Hu et al, 2014). A new predictive model that includes CRP and TNM stage has been developed to evaluate the prognosis of clear cell renal cell carcinoma (Iimura et al, 2009).…”

Section: Discussionsupporting

confidence: 80%

“…However, CRP is also a nonspecific biomarker, and the elevation of CRP is observed under the conditions of myocardial infarction, trauma and cancer (Gabay et al, 1999). Recently, the relationship between CRP and prognosis of cancer was further investigated in renal cell carcinoma (Hu et al, 2014), gastric cancer (Yu et al, 2013), hepatocellular carcinoma (Zheng et al, 2013) and lung cancer (Zhou et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Value of C-Reactive Protein in Esophageal Cancer: a Meta-analysis

Zheng

Cao²,

Cui³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The classical inflammatory biomarker, C-reactive protein (CRP), has been identified to be related to progression of esophageal cancer. Some research showed that elevated pretreatment serum CRP indicated a poor prognosis, but results have been inconsistent. Materials and Methods: We searched the Medline, Embase and the Cochrane Central Search Library for suitable studies and a meta-analysis of eleven (1,886 patients) was conducted to examine the relationship between elevated serum CRP level and overall survival (OS) in esophageal cancer cases. Moreover, correlation analyses were conducted to assess links between pretreatment serum CRP level and tumor node metastasis (TNM) stage as well as T, N, M grade, respectively. Results: The pooled analysis showed that elevated pretreatment serum CRP level was significantly associated with poorer overall survival (HR 2.09, 95%CI 1.52-2.87, p<0.01). Subgroup analyses were conducted by "country", "cut-off value", "treatment" and "number of patients", and no single factor could alter the result. Elevated pretreatment serum CRP was significantly correlated with more advanced TNM stage and T, N, M grade respectively. Conclusions: Elevated pretreatment serum CRP levels are associated with poorer prognosis in esophageal cancer patients, and could serve as a useful biomarker for outcome prediction.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Introductionmentioning

confidence: 99%

Prognostic Value of C-Reactive Protein in Esophageal Cancer: a Meta-analysis

Zheng

Cao²,

Cui³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…During the past decade, numerous studies explored the prognostic impact of CRP in urological cancers, including renal cell cancer, prostate cancer, bladder cancer and upper urinary urothelial carcinoma [19,20] . Another re- 305 cent meta-analysis showed that elevated CRP level in patients with RCC is associated with poorer prognosis and therefore could serve as a useful biomarker for clinical prediction [21] . To our knowledge, this is the first study designed to specifically examine the CRP levels in patients with mRCC who underwent CN and to evaluate CRP as an independent prognostic factor for these patients.…”

Section: Discussionmentioning

confidence: 99%

Preoperative C-Reactive Protein Values as a Potential Component in Outcome Prediction Models of Metastasized Renal Cell Carcinoma Patients Receiving Cytoreductive Nephrectomy

Kalogirou

Mulfinger²,

Sokolakis³

et al. 2017

Urol Int

View full text Add to dashboard Cite

Purpose: To validate preoperative C-reactive protein (CRP) levels as a prognostic marker for survival in a metastasized renal cell carcinoma (mRCC) patient cohort receiving cytoreductive nephrectomy (CN). Patients and Methods: By chart review, 146 mRCC patients receiving CN at our tertiary referral centre from 1997 to 2015 were identified retrospectively. All relevant clinicopathological features including laboratory parameters were collected and correlated to overall survival, progression-free survival and cancer-specific survival (CSS). The mean follow-up was 23 months (range 1-168 months). Results: Besides the already established scoring systems like the MSKCC criteria, an elevated preoperative CRP level (≥0.5 mg/dL) was an independent predictor of CSS in our study group including the chosen postoperative adjuvant therapies (TKI vs. immunotherapy vs. others). With regard to morbidity, patients with a good performance status, small tumour size and adequate renal function/haematopoiesis experienced less complication rates, thereby profiting more from CN. Conclusions: Our data provide indication that preoperative CRP levels should be implemented in nomograms regarding the outcome prediction in mRCC to identify candidates likely to profit from CN.

show abstract

“…15 Patients with advanced RCC sometimes show paraneoplastic syndrome with fever and leukocytosis. The involvement of several molecules related to inflammation, such as interleukin-6 , 16 nuclear factor-kappa B, 17 and CRP, 10,11,13 on the progression of RCC have been previously demonstrated. A high NLR is associated with a poor prognosis in many solid tumours.…”

Section: Discussionmentioning

confidence: 91%

“…8,9 Parameters of inflammatory response, such as C-reactive protein (CRP), have been reported as prognostic markers in urological cancers. [10][11][12] The implication of CRP for predicting the prognosis or the effect of agents has also been demonstrated with targeted therapy in RCC. 13 Besides CRP, the elevation of the neutrophils-to-lymphocytes ratio (NLR) has been reported as a prognostic factor in cancers, including RCC.…”

Section: Introductionmentioning

confidence: 99%

Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasis

Teishima

Ohara

Sadahide

et al. 2017

CUAJ

View full text Add to dashboard Cite

Introduction: The aim of our present study was to investigate the impact of the pretreatment neutrophil-to-lymphocyte ratio (NLR) on the antitumour effects of targeted agents in patients with metastatic renal cell carcinoma (mRCC). Methods: The NLRs in 283 cases of molecular targeted therapy for mRCC were measured before starting the prescription of the molecular targeted agent. The significance of pretreatment NLR on the site of metastatic organs and on progression-free survival (PFS) in each case was analyzed. Results: Metastases other than lung, which is defined as "extrapulmonary metastasis," were observed in 190 cases (67.1%). The median of pretreated NLR was 2.39 (0.49-68.7). In 97 of the 283 cases, pretreated NLR was 3.0 or higher. These cases were categorized as the high NLR group and the rest as the low NLR group. When the cases with extrapulmonary metastasis were investigated and classified based on their pretreated NLR, 50% PFS in the high NLR and low NLR groups was 6.7 months and 12 months (p=0.0001), respectively. Multivariate analysis revealed that high NLR (>3.0) was an independent predictive factor for PFS in the cases with extrapulmonary metastasis (hazard ratio 2.762; p<0.0001), while there was no significant difference between PFS in the high and low NLR groups in cases with no extrapulmonary metastasis (p=0.3457). Conclusions: Our data indicate that the predictive significance of the NLR in mRCC cases involving targeted therapy depends on the metastatic organs. NLR is an independent predictive factor of PFS in cases of mRCC with extrapulmonary metastasis treated with targeted therapy.

show abstract

The prognostic value of C-reactive protein in renal cell carcinoma: A systematic review and meta-analysis

Cited by 66 publications

References 37 publications

Prognostic Value of C-Reactive Protein in Esophageal Cancer: a Meta-analysis

Prognostic Value of C-Reactive Protein in Esophageal Cancer: a Meta-analysis

Preoperative C-Reactive Protein Values as a Potential Component in Outcome Prediction Models of Metastasized Renal Cell Carcinoma Patients Receiving Cytoreductive Nephrectomy

Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasis

Contact Info

Product

Resources

About